Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Homologous equivalence study of immunogenicity after third dose of Covid-19 vaccine (recombinant) with an interval of six months after the second dose, comparing the interval of eight and 12 weeks between the first two doses

2024; Instituto Oswaldo Cruz, Ministério da Saúde; Volume: 119; Linguagem: Inglês

10.1590/0074-02760240094

ISSN

1678-8060

Autores

Clarice Monteiro Vianna, Glória Regina da Silva e Sá, Maria Vitória Hadland Seid, Luiz Antônio Bastos Camacho, Janaína Reis Xavier, Vitor Cardoso da Gama, Thalita da Matta de Castro, Ewerton Alves Portela dos Santos, Camila Dias de Almeida, Robson Leite de Souza Cruz, Marilda Mendonça Siqueira, Maria de Lourdes de Sousa Maia, Clara Lucy de Vasconcellos Ferroco, Mia Ferreira de Araújo, Luis Fernando López Tort, Bráulia Costa Caetano,

Tópico(s)

Biosimilars and Bioanalytical Methods

Resumo

In response to the coronavirus disease 2019 (Covid-19) pandemic, Brazil authorised the Astra Zeneca/Fiocruz vaccine in January 2021. As the Delta variant emerged in May 2021, interval between vaccine doses was adjusted. By September 2021, the Brazilian National Immunisation Program recommended a booster dose for individuals over 70, and later expanded the recommendation to all adults.

Referência(s)